<DOC>
	<DOCNO>NCT01405430</DOCNO>
	<brief_summary>It prospective , non-randomized , monocentric study . The purpose study assess predictive value VE-cadherin objective tumor response . Biological factor correlate clinical outcome measure . 100 patient treat bevacizumab metastatic colorectal adenocarcinoma enrol . Patients follow every 10 week progression spite bevacizumab stop bevacizumab toxicity . Bevacizumab administer accord investigator appreciation . Blood sample collect enrollment , second bevacizumab 's administration every 10 week progression , patient stop bevacizumab toxicity one year case patient still receive bevacizumab .</brief_summary>
	<brief_title>Exploration Circulating VE-cadherin Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient metastatic colorectal cancer prove histologically treat bevacizumab first line . At least one extraosseous , nonirradiated , measurable site ( &gt; = 10 mm spiral CT ) . No prior radiotherapy treatment unless treatment least 4 week . Adult patient . PS &lt; = 2 . Life expectancy great 3 month . Mandatory affiliation healthy security insurance . Signed write informed consent . Prior chemotherapy metastatic cancer . Prior bevacizumab treatment . Other current cancer previous cancer detect last 5 year link current disease . Patient deprive freedom . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>